The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer

Radiotherapy plus cetuximab or cisplatin in human papillomavirus

Randomized Phase III Trial of Concurrent Accelerated Radiation

Avelumab–cetuximab–radiotherapy versus standards of care in

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin

Neoadjuvant cisplatin and fluorouracil versus epirubicin

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic

Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in

Gemcitabine–cisplatin versus MVAC chemotherapy for urothelial

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil

Frontiers Cetuximab-Containing Combinations in Locally Advanced